Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AVBP
SellSinkerArriVent BioPharma, Inc. · Healthcare · United States · $1.5B · Avg Vol: $12M/d
COMPANY DESCRIPTION
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly in areas with high unmet medical need, with a lead candidate targeting specific mutations in non-small cell lung cancer. The company relies on its scientific expertise in precision oncology and strategic partnerships to advance its pipeline. It is a focused biopharma company specializing in precision oncology, with a pipeline aimed at specific genetic targets in cancer.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 29.7M | — |
| EPS | -1.15 | -2.17 | -2.56 | -4.32 | — | -3.55 | -4.34 | -3.81 | — |
| Shares | 32.0M | 32.0M | 33.7M | 42.5M | +32.8% | 49.3M | — | — | — |
| Debt | 0.1M | 0.3M | 0.2M | 14.0K | -53.5% | 0.4M | — | — | — |
| Equity | -85.1M | -153.2M | 257.7M | 307.2M | 19.2% | — | — | — | — |
| Op CF | -43.6M | -55.8M | -70.2M | -160.6M | — | -147.9M | — | — | — |
| Inv CF | 0 | 0 | -192.5M | -71.2M | — | — | — | — | — |
| Fin CF | 169.7M | 42.9M | 186.6M | 203.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVBP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc.(you) | $1.5B | 21 | Sell |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.4B | 21 | Sell |
| VOR | Vor Biopharma Inc. | $1.3B | 20 | Sell |
| REPL | Replimune Group, Inc. | $1.5B | 18 | Strong Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 21 | Sell |
| ABSI | Absci Corporation | $1.5B | 17 | Strong Sell |
| MNKD | MannKind Corporation | $1.3B | 24 | Sell |
| JBIO | Jade Biosciences, Inc. | $1.3B | 25 | Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 22 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%